1. Home
  2. REPL vs BTO Comparison

REPL vs BTO Comparison

Compare REPL & BTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$9.93

Market Cap

781.3M

Sector

Health Care

ML Signal

HOLD

Logo John Hancock Financial Opportunities Fund

BTO

John Hancock Financial Opportunities Fund

HOLD

Current Price

$35.12

Market Cap

673.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
REPL
BTO
Founded
2015
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
781.3M
673.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
REPL
BTO
Price
$9.93
$35.12
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
1.6M
54.2K
Earning Date
02-11-2026
01-01-0001
Dividend Yield
N/A
9.13%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.68
$22.95
52 Week High
$14.80
$32.81

Technical Indicators

Market Signals
Indicator
REPL
BTO
Relative Strength Index (RSI) 54.60 46.53
Support Level $9.70 $35.10
Resistance Level $10.27 $36.00
Average True Range (ATR) 0.38 0.53
MACD -0.08 -0.15
Stochastic Oscillator 55.35 0.00

Price Performance

Historical Comparison
REPL
BTO

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About BTO John Hancock Financial Opportunities Fund

John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The company invests in banks, capital markets, Insurance, Mortage Real Estate Investment trust, Health Care REITs, Diversified REITs, Office REITs.

Share on Social Networks: